Fighting Melanoma: Join LFFM on Jan 28

Listen on Audio:

Watch on YouTube:

Join LFFM London: Wednesday, 28 January 2026 | British Museum | 7pm Leveraged Finance Fights Melanoma (LFFM) London brings together leaders from the European leveraged finance and private credit community to raise critical funds for cutting-edge melanoma research. Learn more: https://www.curemelanoma.org/get-involved/events/leveraged-finance-fights-melanoma

Season 3, Episode 1 

On this episode of LFI Levered Lines, host Luke Millar is joined by Peter Urquhart, melanoma survivor and Global Senior Manager at LSEG, and Stephanie Kauffman, President and Chief Operating Officer of Melanoma Research Alliance, for an in-depth discussion of groundbreaking cancer research and the upcoming LFFM London event. The conversation examines Peter’s personal journey through stage 3 melanoma diagnosis at age 37, his 12-month immunotherapy treatment with minimal side effects, and his nine-month clear status, alongside the remarkable expansion from two to seventeen approved melanoma treatment options over the past 15 years and the 50% patient response rate representing quantum leaps in oncology outcomes. Stephanie discusses the alarming trend of melanoma cases in younger populations, the revolutionary development of immunotherapy now benefiting 30 other cancers, and the critical importance of early detection through AI-powered technologies being developed at Oxford University and Royal Marsden. The discussion highlights the inaugural LFFM London success—raising £1.4 million with 550 attendees—alongside research priorities addressing genetic mutations, brain metastasis, and reducing treatment side effects.

Luke and Stephanie explore how all London-raised funds stay within the UK research community, the upcoming venue expansion to the British Museum to accommodate demand, and the increasing engagement from younger patients seeking early intervention. Looking ahead to January 28, 2026, they analyze how 70 committed firms and 600+ expected guests will continue building the Leverage Finance community’s £32 million total contribution to melanoma research and the transformative impact on cancer treatment development. This episode delivers essential insights for the Leverage Finance community supporting life-changing cancer research and anyone interested in understanding how melanoma breakthroughs are pioneering treatments across multiple cancer types.